Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor - ViDoe

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

85 views

OBRoncology

8 years ago

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

2:34

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

1:54

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

1:46

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

Jeffrey Weber Explains Organ-Specific Side Effects of Checkpoint Inhibitors

1:51

Jeffrey Weber Explains Organ-Specific Side Effects of Checkpoint Inhibitors

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

1:28

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

by Targeted Oncology

$Dr. Jeffrey Weber on Potential Breakthrough \\$

1:21

Dr. Jeffrey Weber on Potential Breakthrough \\"Cures\\" in Melanoma

by Targeted Oncology

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

1:26

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

2:00

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

1:23

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

2:26

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease Burden

2:20

Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease Burden

by Targeted Oncology

Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response

0:57

Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response

by Targeted Oncology

Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma

1:03

Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma

Dr. Jeffrey Weber on Ipilimumab for Melanoma

1:55

Dr. Jeffrey Weber on Ipilimumab for Melanoma

Dr Jeffrey Weber explains his approach to immunotherapy-induced colitis

10:09

Dr Jeffrey Weber explains his approach to immunotherapy-induced colitis

by Journal of Immunotherapy and Precision Oncology

Cancer Revealed: How the Immune System Sees and Destroys Tumors, with Jeffrey Weber

1:02:36

Cancer Revealed: How the Immune System Sees and Destroys Tumors, with Jeffrey Weber

by Cancer Research Institute

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

1:28

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

Adjuvant and Neoadjuvant Dilemmas

27:18

Adjuvant and Neoadjuvant Dilemmas

by AIMatMelanoma

$Jeffrey Weber, MD, PhD: The Impact of BRAF\/MEK Inhibitors in Melanoma$

1:28

Jeffrey Weber, MD, PhD: The Impact of BRAF\/MEK Inhibitors in Melanoma

by Targeted Oncology

PD-1 Inhibitor Use in Melanoma

5:37

PD-1 Inhibitor Use in Melanoma